Additionally, the SAM+anti-PD-1 treated group had the highest percentage of tumor volume reduction (69%, p < 0.0001) relative to control as compared to SAM and anti-PD-1 alone (37 and 44%, respectively) at the end point (Figure 2B). Here, PDCD1 is linked to neoplasm.